A patient is described who developed porokeratosis of Mibelli following treatment with prednisolone and azathioprine for chronic active hepatitis. Immunosuppression is recognized to predispose to the development of porokeratosis and to cause the spread of pre-existing lesions. Porokeratosis is believed to represent a clone of mutant epidermal cells and immunosuppression may impair the processes which normally contain these cells, allowing the extension of existing lesions or the initiation of new ones. We consider that immunosuppression may be an important contributing factor to the development of porokeratosis in our patient.
Case report
A 63-year-old retired publican presented with two lesions on the right arm which had been present since 1978.There was no family history of skin disease.
In 1971 he had developed general malaise and was noted to have hepatomegaly, jaundice and the stigmata of chronic liver disease. A liver biopsy showed cirrhosis with no active inflammation and in view of a reported low alcohol intake and a negative hepatitis B surface antigen, he was considered to have cirrhosis secondary to an autoimmune chronic active hepatitis. He was initially treated with prednisolone 30 mg daily, which after three months was reduced to 15mg daily. He continued on this therapy until 1977 when he developed osteoporosis of the thoracic and lumbar vertebrae. The prednisolone was reduced to 5 mg daily and azathioprine 50 mg was started.
In September 1985,at review of his liver disease, he volunteered that he had had a high alcohol intake until 1971. Review of his investigations suggested that there was no support for a diagnosis of autoimmune chronic active hepatitis and the diagnosis was changed to alcoholic cirrhosis. The azathioprine was stopped and the prednisolone is gradually being tailed off.
During this admission he was noted to have two lesions on the right upper arm. One was located on the medial aspect of the arm and comprised an erythematous, scaly plaque at the periphery of which was a heaped up rim of scale ( Figure 1 ). The second lesion was located in the lateral aspect of the arm and 
Discussion
Porokeratosis of Mibelli is an inherited disorder characterized by an abnormality in the process of maturation in the epidermal keratinocytes. The lesions usually appear in childhood or adolescence and the limbs are the most commonly affected site. It is a slowly progressive condition, but rapid extension has followed treatment with the thiazide diuretic benzylhydrochlorothiaaide' and immunosuppressive therapy'. Various clinical forms of porokeratosis have been described: a localized plaque type and a linear and a disseminate form:'. Disseminate superficial actinic porokeratosis (DSAP) is a further distinct variety ofporokeratosis in which lesions appear in middle age and are confined to sun-exposed sites".
The patient described here is unusual because he has developed the classical plaque form of porokeratosis of Mibelli late in life. Prior to the onset of the lesions he had been treated with long-term immunosuppressive therapy. In the light of previous reports describing both the development' and extension? of porokeratosis following immunosuppression, we consider that our patient's immunosuppressive therapy may be an important aetiological factor in the development of his lesions. In a case reported by MacMillan and Roberts", the lesions of porokeratosis had been present since childhood; two weeks after the start of immunosuppression for renal transplantation there was spread ofthe original lesion and many new lesions appeared. Subsequent reduction of the immunosuppressive therapy has been associated with a reduction in the number ofnew lesions emerging (personal communication). This would appear to lend support to their view that the onset of the' Journal of the Royal Society of Medicine Volume 80 March 1987 181 porokeratosis was related to the immunosuppressive therapy. A second report." described two cases, in one of whom DSAP-like lesions spread five days after the start of chemotherapy for acute myeloid leukaemia (AML), and in the other porokeratosis developed on the buttock one year after bone marrow grafting for AML.
Reed and Leone" have attempted to explain the histiogenesis ofporokeratosis by suggesting that the porokeratotic areas represent a clone of abnormal epidermal cells capable of spreading outwards at the expense of the normal epidermis. The extension and appearance of porokeratosis in an immunosuppressed patient has been explained on the basis that the abnormal cells are held in check either by adjacent normal epidermal cells or by classical immune mechanisms; immunosuppressive therapy may impair either of these mechanisms, leading to the spread or development of porokeratosis", Reed and Leone" likened the histiogenesis of porokeratosis to that of solar keratoses, which they also regard as a clonal disease of the epidermis. The incidence of solar keratoses and cutaneous malignancies in immunosuppressed renal transplant recipients is higher than in the normal population7. This may be explained by the theory of immunesurveillance", which proposes that the immune system may function as a defence system against newly arising transformed cells; defects in immunity and subsequent decreased immunosurveillance may be important in the pathogenesis of the tumours observed in renal transplant recipients". Likewise, a loss of immunosurveillance may be equally relevant to the pathogenesis of porokeratosis in immunosuppressed individuals.
Whilst immunosuppressive therapy is commonly used for a variety of conditions, the association between porokeratosis and immunosuppression is rare. Presumably only certain genetically predisposed subjects are susceptible.
